For the Inventor, By the Inventor

Enter assignee name

Lausanne, Switzerland

Amazentis Sa

USPTO Granted Patents = 40

CIPO Patents = 1

EPO Patents = 15

Trademarks = 17

Forward Citations = 274

Loading Chart...

Loading Chart...

31 inventors (with patents filed for the assignee):

Christopher Rinsch (37 out of 50 patents)

Penelope Andreux (28 out of 32 patents)

William Blanco-Bose (26 out of 26 patents)

4. Johan Auwerx (15 out of 21 patents)

5. Bernard Schneider (15 out of 19 patents)

6. Laurent Mouchiroud (15 out of 17 patents)

7. Carmen Sandi (9 out of 10 patents)

8. Eija Pirinen (9 out of 9 patents)

9. David Genoux (9 out of 9 patents)

10. Dongryeol Ryu (6 out of 7 patents)

11. Charles Thomas (6 out of 6 patents)

12. Richardus Houtkooper (6 out of 7 patents)

13. Wolfgang Skranc (5 out of 16 patents)

14. Anurag Singh (5 out of 7 patents)

15. Davide D'Amico (4 out of 4 patents)

Core Competencies:

Urolithin A

Mitochondrial Function

Neurodegenerative Diseases

Autophagy Enhancement

Immune Response

Nicotinamide Riboside

Prodrugs

Cognitive Disorders

Formulations

Synthesis

Brain Health

Longevity

40 patents: Sort by Forward Citations

1. 12576065 - Enhancing autophagy or increasing longevity by administration of urolithins (2026-03-17),

2. 12576064 - Urolithin gummy (pectin) formulations (2026-03-17),

3. 12544358 - Enhancing autophagy or increasing longevity by administration of urolithins (2026-02-10),

4. 12338224 - Process-scale synthesis of urolithin A (2025-06-24),

5. 12310943 - Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders (2025-05-27),

6. 12297182 - Compositions comprising an urolithin compound (2025-05-13),

7. 12220424 - Compositions comprising nicotinamide riboside and a urolithin (2025-02-11),

8. 12109190 - Urolithins as immune response enhancers (2024-10-08),

9. 12036205 - Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders (2024-07-16),

10. 12030863 - Prodrugs of urolithins and uses thereof (2024-07-09),

11. 11969408 - Method for improving mitophagy in subjects (2024-04-30),

12. 11931336 - Enhancing autophagy or increasing longevity by administration of urolithins (2024-03-19),

13. 11931335 - Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof (2024-03-19),

14. 11925616 - Compositions comprising urolithin compounds (2024-03-12),

15. 11903922 - Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders (2024-02-20),

Company Overview

Amazentis is a biotechnology company based in Lausanne, Switzerland, specializing in the development of innovative health solutions. The organization focuses on harnessing the power of cellular health and metabolism to create products that enhance human performance and well-being. With a strong emphasis on research and development, Amazentis explores advanced technologies in the fields of nutrition and biochemistry, aiming to translate scientific discoveries into effective health interventions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

40 Patents

#10 in Lausanne

#343 in Switzerland

#17,068 in the World

Lausanne, Switzerland

Amazentis Sa

Forward Citations = 274

31 inventors:

Christopher Rinsch (37 out of 50 patents)

Penelope Andreux (28 out of 32 patents)

William Blanco-Bose (26 out of 26 patents)

4. Johan Auwerx (15 out of 21 patents)

5. Bernard Schneider (15 out of 19 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Amazentis Sa. Retrieved from https://idiyas.com/company/amazentis-sa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…